Skip to content

rTMS Treatment of Primary Progressive Aphasia

Repetitive Transcranial Magnetic Stimulation in the Treatment of Primary Progressive Aphasia: A Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04431401
Enrollment
40
Registered
2020-06-16
Start date
2020-07-01
Completion date
2022-08-31
Last updated
2024-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Progressive Aphasia, Repetitive Transcranical Magnetic Stimulation

Brief summary

Primary Progressive Aphasia (PPA) is a neurodegenerative disease in which language function is gradually and progressively impaired. Patients will eventually be disabled in communication and have cognition deficits, which put a heavy burden not only on their families but also on the whole society. However, no effective treatment for PPA has been explored so far. The current clinical randomized trial is to study the safety and efficacy of repetitive Transcranial Magnetic Stimulation (rTMS) for the treatment of PPA. Also, multi-modality of neuroimaging techniques, such as functional MRI and PET will be used to investigate brain network changing in this procedure.

Interventions

The device is made in London,UK

Sponsors

Peking Union Medical College Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
35 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Clinical diagnosis of PPA

Exclusion criteria

* Scored below 15 on the mini-mental state exam (MMSE) * history of seizures or unexplained loss of consciousness * pregnancy * surgical breach of the skull * MRI contraindication

Design outcomes

Primary

MeasureTime frameDescription
Western Aphasia Battery (WAB) Speech fluency1 day before the treatmentAssessment of the language production. Scores range from 0 to 20. Higher scores means better outcome.
Western Aphasia Battery (WAB) Word recognition1 day before the treatmentAssessment of the reading. Scores range from 0 to 60. Higher scores means better outcome.
Syntax comprehension part of Bilingual aphasia test (Standard Modern Chinese Version)1 day before the treatmentAssessment of the grammar ability. Scores range from 0 to 50. Higher scores means better outcome.
Boston naming test evaluation1 day before the treatmentAssessment of the language production. Scores range from 0 to 30. Higher scores means better outcome.
Western Aphasia Battery (WAB) Repetition1 day before the treatmentAssessment of the repetition ability. Scores range from 0 to 100. Higher scores means better outcome.

Secondary

MeasureTime frameDescription
Standardized Uptake Value (SUV)1 day before the treatmentPET parameter to evaluate brain metabolism
functional connectivity map (FC map)1 day before the treatmentFunctional Connectivity was examined using a seed-based voxel-wise correlation approach. The language related brain areas, such as Broca Area and Wernicke Area, were defined as the regions of interest (ROI). Pearson's correlation analysis between the time course of the ROI and that of every voxel in the whole brain was computed for a map of correlation coefficients, which were Fisher's z-transformed and called as z-FC maps. This outcome measurement, the z-FC map, is not numeric data. Z-FC map is a radiographic imaging measurement.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026